Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

B. Riley Securities Maintains Buy on Novavax, Raises Price Target to $29

Author: Benzinga Newsdesk | May 23, 2024 09:27am
B. Riley Securities analyst Mayank Mamtani maintains Novavax (NASDAQ:NVAX) with a Buy and raises the price target from $11 to $29.

Posted In: NVAX